1. Efficacy, Immunogenicity, and Safety of the Bivalent RSV Prefusion F (RSVpreF) Vaccine in Older Adults Over 2 RSV Seasons.
- Author
-
Walsh EE, Eiras D, Woodside J, Jiang Q, Patton M, Marc GP, Llapur C, Rämet M, Fukushima Y, Hussen N, Cardona J, Mikati T, Zareba A, Ilangovan K, Lino MM, Kalinina EV, Swanson KA, Gurtman A, and Munjal I
- Abstract
Background: RSV is an important cause of lower respiratory tract illness (LRTI) in older adults. RSVpreF is a bivalent stabilized prefusion F vaccine containing antigens against RSV-A and RSV-B. In this phase 3 trial in ≥60-year-olds, RSVpreF demonstrated vaccine efficacy (VE) of 88.9% and 77.8% against RSV-associated LRTI with ≥3 symptoms at the end of RSV seasons 1 and 2, respectively. Here we describe final safety and efficacy results and present immunogenicity data., Methods: This study was conducted over 2 RSV seasons. Participants were randomized (1:1) to 1 dose of RSVpreF 120-µg or placebo. A secondary objective was to describe RSVpreF immunogenicity 1-month postvaccination and before season 2 visits in a participant subset from the USA and Japan., Results: One-month postvaccination neutralization titer geometric mean fold rise (GMFR) was 12.1 for combined RSV-A/RSV-B. Geometric mean titers decreased at the preseason 2 visit, but remained substantially higher than baseline (RSV-A/RSV-B GMFR=4.7). One month postvaccination, GMFRs for RSV-A/RSV-B neutralizing responses ranged from 12.0-13.0 for subgroups stratified by age (60-69, 70-79, ≥80 years). RSV-A/RSV-B GMFRs in participants with prespecified chronic conditions were generally similar to those without (range, 11.4-14.4). A consistent favorable safety profile and durable VE was seen through 2 RSV seasons., Conclusion: High RSV neutralizing titers were observed 1 month after RSVpreF vaccination in ≥60-year-olds, with similarly robust responses across age subgroups and baseline chronic conditions. These robust immune responses corresponded with high RSVpreF VE against RSV-associated LRTI. RSVpreF had a favorable safety profile over 2 seasons.NCT05035212; EudraCT, 2021-003693-31., (© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2025
- Full Text
- View/download PDF